Ted W. Love, MD, president and CEO of Global Blood Therapeutics (GBT), defended the list price of his company’s recently-approved sickle-cell disease drug Oxbryta™ (voxelotor) before an audience of investors in New York . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge